Literature DB >> 15908802

Vector-mediated cancer gene therapy: an overview.

Prem Seth1.   

Abstract

In recent years there has been a dramatic increase in developing gene therapy approaches for the treatment of cancer. The two events that have permitted the formulation of concept of cancer gene therapy are the new understanding of the molecular mechanisms underlying oncogenesis, and the development of the DNA-delivery vehicles or vectors. Many approaches to cancer gene therapy have been proposed, and several viral and non-viral vectors have been utilized. The purpose of this review article is to describe the various strategies of cancer gene therapy (transfer of tumor suppressor genes, suicide genes-enzyme/pro-drug approach, inhibition of dominant oncogenes, immunomodulation approaches, expression of molecules that affect angiogenesis, tumor invasion and metastasis, chemosensitization and radiosensitization approaches, and chemoprotection of stem cells). The chapter also reviews the commonly used vectors (retroviral vectors, adenoviral vectors, adeno-associated viral vectors, pox viruses, herpes simplex viruses, HIV- vectors, non-viral vectors and targetable vectors) for cancer gene therapy. Some of the important issues in cancer gene therapy, and the potential future directions are also being discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15908802     DOI: 10.4161/cbt.4.5.1705

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  16 in total

1.  The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma.

Authors:  Jian Gang Pan; Xing Zhou; Runqi Luo; Rui Fa Han
Journal:  Med Oncol       Date:  2011-10-20       Impact factor: 3.064

2.  Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.

Authors:  M Trepel; J Körbelin; E Spies; M B Heckmann; A Hunger; B Fehse; H A Katus; J A Kleinschmidt; O J Müller; S Michelfelder
Journal:  Gene Ther       Date:  2015-06-02       Impact factor: 5.250

3.  Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model.

Authors:  Carina Riediger; Gerhard Wingender; Percy Knolle; Sebastian Aulmann; Wolfgang Stremmel; Jens Encke
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-10       Impact factor: 4.553

Review 4.  Evolving gene therapy approaches for osteosarcoma using viral vectors: review.

Authors:  M A Witlox; M L Lamfers; P I J M Wuisman; D T Curiel; G P Siegal
Journal:  Bone       Date:  2006-12-26       Impact factor: 4.398

5.  Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer.

Authors:  Keng-Li Lan; Fu Ou-Yang; Sang-Hue Yen; How-Ling Shih; Keng-Hsin Lan
Journal:  Clin Exp Metastasis       Date:  2010-04-07       Impact factor: 5.150

6.  INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.

Authors:  Hong-Wei Wang; Mary B Breslin; Chiachen Chen; Victoria Akerstrom; Qiu Zhong; Michael S Lan
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

Review 7.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

8.  Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma.

Authors:  Chun-Ann Chen; Cheng-Kai Lo; Bai-Ling Lin; Eric Sibley; Shiue-Cheng Tang
Journal:  Cancer Biol Ther       Date:  2007-11-21       Impact factor: 4.742

9.  Promoters with cancer cell-specific activity for melanoma gene therapy.

Authors:  V V Pleshkan; I V Alekseenko; M V Zinovyeva; T V Vinogradova; E D Sverdlov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

10.  A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.

Authors:  Z Hu; J S Robbins; A Pister; M B Zafar; Z-W Zhang; J Gupta; K J Lee; K Newman; K Neuman; C-O Yun; T Guise; P Seth
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.